Psilocybin Has Better Response Than Placebo in Antidepressant Trials
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 28, 2024 -- Patients treated with high-dose psilocybin have better responses than those treated with placebo in antidepressant trials, according to a study published online Aug. 21 in The BMJ.
Tien-Wei Hsu, M.D., from E-DA Dachang Hospital in Kaohsiung, Taiwan, and colleagues examined the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients with depressive symptoms in a systematic review and Bayesian network meta-analysis. The primary outcome was change in depression, which was measured by the 17-item Hamilton Depression Rating Scale.
The researchers found that compared with antidepression trials of escitalopram, placebo response in psychedelic trials was lower (mean difference, −3.90). Most psychedelics were better than placebo in psychedelic trials, but in antidepression trials of escitalopram, only high-dose psilocybin was better than placebo (mean difference, 6.45). When the reference arm changed from placebo response in the psychedelic trials to antidepressant trials, the effect size of high-dose psilocybin decreased from large to small (standardized mean difference, 0.88 to 0.31, respectively). Compared with escitalopram at 10 mg and 20 mg, the relative effect of high-dose psilocybin was larger (4.66 and 4.69, respectively). Of the interventions, none were associated with higher all-cause discontinuation or severe adverse events than the placebo.
"Serotonergic psychedelics, especially high-dose psilocybin, appeared to have the potential to treat depressive symptoms," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Combinations of Chronic, Physical Illnesses Up the Risk of Subsequent Depression
WEDNESDAY, May 21, 2025 -- Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a study published online May 13...
Calorie Restrictions, Low-Fat Diets May Reduce Depressive Symptoms
MONDAY, May 19, 2025 -- Among adults with elevated cardiometabolic risk, calorie restrictions and low-fat diets may reduce depressive symptoms, according to a review published...
Gabapentinoids Not Directly Associated With Risk of Self-Harm
THURSDAY, May 15, 2025 -- Gabapentinoids are not associated with risk of self-harm in adults; however, elevated risk is seen before initiation of treatment, during the initial...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.